Emek Demir
Overview
Explore the profile of Emek Demir including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
3831
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Link J, Eng J, Pelz C, MacPherson-Hawthorne K, Worth P, Sivagnanam S, et al.
Nat Cancer
. 2025 Jan;
6(1):123-144.
PMID: 39789181
Patients with metastatic pancreatic ductal adenocarcinoma survive longer if disease spreads to the lung but not the liver. Here we generated overlapping, multi-omic datasets to identify molecular and cellular features...
2.
Mohammadhosseini M, Enright T, Duvall A, Chitsazan A, Lin H, Ors A, et al.
Sci Transl Med
. 2025 Jan;
17(780):eadn9832.
PMID: 39772771
Familial platelet disorder (FPD) is associated with germline mutations, establishing a preleukemic state and increasing the risk of developing leukemia. Currently, there are no intervention strategies to prevent leukemia progression....
3.
Ak C, Sayar Z, Thibault G, Burlingame E, Kuykendall M, Eng J, et al.
iScience
. 2024 Sep;
27(9):110668.
PMID: 39246442
Mapping the spatial interactions of cancer, immune, and stromal cell states presents novel opportunities for patient stratification and for advancing immunotherapy. While single-cell studies revealed significant molecular heterogeneity in prostate...
4.
Yashar W, Estabrook J, Holly H, Somers J, Nikolova O, Babur O, et al.
iScience
. 2024 Mar;
27(3):109124.
PMID: 38455978
Dysregulation of normal transcription factor activity is a common driver of disease. Therefore, the detection of aberrant transcription factor activity is important to understand disease pathogenesis. We have developed Priori,...
5.
Somers J, Fenner M, Kong G, Thirumalaisamy D, Yashar W, Thapa K, et al.
Proteomics
. 2023 Nov;
23(21-22):e2200402.
PMID: 37986684
For decades, molecular biologists have been uncovering the mechanics of biological systems. Efforts to bring their findings together have led to the development of multiple databases and information systems that...
6.
Kim H, Rames M, Goncalves F, Kirschbaum C, Roskams-Hieter B, Spiliotopoulos E, et al.
Commun Biol
. 2023 Aug;
6(1):885.
PMID: 37644220
Extracellular vesicles (EVs) have been shown as key mediators of extracellular small RNA transport. However, carriers of cell-free messenger RNA (cf-mRNA) in human biofluids and their association with cancer remain...
7.
Yashar W, Curtiss B, Coleman D, VanCampen J, Kong G, Macaraeg J, et al.
Mol Cancer Res
. 2023 Mar;
21(7):631-647.
PMID: 36976323
Implications: This work establishes the synergistic efficacy of combined FLT3 and LSD1 inhibition in FLT3-ITD AML by disrupting STAT5 and GFI1 binding at the MYC blood-specific superenhancer complex.
8.
Braun T, Estabrook J, Schonrock Z, Curtiss B, Darmusey L, Macaraeg J, et al.
Leukemia
. 2022 Dec;
37(2):478-487.
PMID: 36526735
Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis....
9.
Johnson B, Creason A, Stommel J, Keck J, Parmar S, Betts C, et al.
Cell Rep Med
. 2022 Mar;
3(2):100525.
PMID: 35243422
Mechanisms of therapeutic resistance and vulnerability evolve in metastatic cancers as tumor cells and extrinsic microenvironmental influences change during treatment. To support the development of methods for identifying these mechanisms...
10.
Ostaszewski M, Niarakis A, Mazein A, Kuperstein I, Phair R, Orta-Resendiz A, et al.
Mol Syst Biol
. 2021 Dec;
17(12):e10851.
PMID: 34939300
No abstract available.